Adempas

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
11-02-2019
Ciri produk Ciri produk (SPC)
11-02-2019
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
10-04-2014

Bahan aktif:

riociguat

Boleh didapati daripada:

Bayer AG

Kod ATC:

C02KX05

INN (Nama Antarabangsa):

riociguat

Kumpulan terapeutik:

Antihypertensives for pulmonary arterial hypertension

Kawasan terapeutik:

Hypertension, Pulmonary

Tanda-tanda terapeutik:

Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.

Ringkasan produk:

Revision: 9

Status kebenaran:

Authorised

Tarikh kebenaran:

2014-03-26

Risalah maklumat

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE USER
ADEMPAS 0.5 MG FILM-COATED TABLETS
ADEMPAS 1 MG FILM-COATED TABLETS
ADEMPAS 1.5 MG FILM-COATED TABLETS
ADEMPAS 2 MG FILM-COATED TABLETS
ADEMPAS 2.5 MG FILM-COATED TABLETS
riociguat
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Adempas is and what it is used for
2.
What you need to know before you take Adempas
3.
How to take Adempas
4.
Possible side effects
5.
How to store Adempas
6.
Contents of the pack and other information
1.
WHAT ADEMPAS IS AND WHAT IT IS USED FOR
Adempas contains the active substance riociguat. Riociguat is a type
of medicine called a guanylate
cyclase (sGC)-stimulator. It works by widening the pulmonary arteries
(the blood vessels that connect
the heart to the lungs), making it easier for the heart to pump blood
through the lungs. Adempas can be
used to treat adults with certain forms of pulmonary hypertension, a
condition in which these blood
vessels become narrowed, making it harder for the heart to pump blood
through them and leading to
high blood pressure in the vessels. Because the heart must work harder
than normal, people with
pulmonary hypertension feel tired, dizzy and short of breath. By
widening the narrowed arteries,
Adempas leads to an improvement in your ability to carry out physical
activity.
Adempas is used in either of two types of pulmonary hypertension:

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)
.
In CTEPH, the blood vessels of the lung are blocked or narrowed with
blood c
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Adempas 0.5 mg film-coated tablets
Adempas 1 mg film-coated tablets
Adempas 1.5 mg film-coated tablets
Adempas 2 mg film
-
coated tablets
Adempas 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Adempas 0.5 mg film-coated tablets
Each film-coated tablet contains 0.5 mg of riociguat.
Adempas 1 mg film-coated tablets
Each film-coated tablet contains 1 mg of riociguat.
Adempas 1.5 mg film-coated tablets
Each film-coated tablet contains 1.5 mg of riociguat.
Adempas 2 mg film-coated tablets
Each film-coated tablet contains 2 mg of riociguat.
Adempas 2.5 mg film-coated tablets
Each film-coated tablet contains 2.5 mg of riociguat.
Excipient with known effect
_Adempas 0.5 mg film-coated tablets _
Each 0.5 mg film-coated tablet contains 37.8 mg lactose (as
monohydrate).
_Adempas 1 mg film-coated tablets _
Each 1 mg film-coated tablet contains 37.2 mg lactose (as
monohydrate).
_Adempas 1.5 mg film-coated tablets _
Each 1.5 mg film-coated tablet contains 36.8 mg lactose (as
monohydrate).
_Adempas 2 mg film-coated tablets _
Each 2 mg film-coated tablet contains 36.3 mg lactose (as
monohydrate).
_Adempas 2.5 mg film-coated tablets _
Each 2.5 mg film-coated tablet contains 35.8 mg lactose (as
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).

_0.5 mg tablet:_
white, round, biconvex tablets of 6 mm, marked with the Bayer cross on
one side
and 0.5 and an “R” on the other side.

_1 mg tablet:_
pale yellow, round, biconvex tablets of 6 mm, marked with the Bayer
cross on one
side and 1 and an “R” on the other side.

_1.5 mg tablet:_
yellow-orange, round, biconvex tablets of 6 mm, marked with the Bayer
cross on
one side and 1.5 and an “R” on the other side.
3

_2 mg tablet:_
pale orange, round, biconvex tablets of 6 mm, marked with the Bayer
cross on one
side and 2 and an “R” on the other side.

_2.5 mg tablet:_
red-orange, round, biconv
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 31-08-2023
Ciri produk Ciri produk Bulgaria 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 01-08-2023
Risalah maklumat Risalah maklumat Sepanyol 31-08-2023
Ciri produk Ciri produk Sepanyol 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 01-08-2023
Risalah maklumat Risalah maklumat Czech 31-08-2023
Ciri produk Ciri produk Czech 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 01-08-2023
Risalah maklumat Risalah maklumat Denmark 31-08-2023
Ciri produk Ciri produk Denmark 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 01-08-2023
Risalah maklumat Risalah maklumat Jerman 31-08-2023
Ciri produk Ciri produk Jerman 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 01-08-2023
Risalah maklumat Risalah maklumat Estonia 31-08-2023
Ciri produk Ciri produk Estonia 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 01-08-2023
Risalah maklumat Risalah maklumat Greek 31-08-2023
Ciri produk Ciri produk Greek 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 01-08-2023
Risalah maklumat Risalah maklumat Perancis 31-08-2023
Ciri produk Ciri produk Perancis 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 01-08-2023
Risalah maklumat Risalah maklumat Itali 31-08-2023
Ciri produk Ciri produk Itali 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 01-08-2023
Risalah maklumat Risalah maklumat Latvia 31-08-2023
Ciri produk Ciri produk Latvia 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 01-08-2023
Risalah maklumat Risalah maklumat Lithuania 31-08-2023
Ciri produk Ciri produk Lithuania 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 01-08-2023
Risalah maklumat Risalah maklumat Hungary 31-08-2023
Ciri produk Ciri produk Hungary 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 01-08-2023
Risalah maklumat Risalah maklumat Malta 31-08-2023
Ciri produk Ciri produk Malta 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 01-08-2023
Risalah maklumat Risalah maklumat Belanda 31-08-2023
Ciri produk Ciri produk Belanda 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 01-08-2023
Risalah maklumat Risalah maklumat Poland 31-08-2023
Ciri produk Ciri produk Poland 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 01-08-2023
Risalah maklumat Risalah maklumat Portugis 31-08-2023
Ciri produk Ciri produk Portugis 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 01-08-2023
Risalah maklumat Risalah maklumat Romania 31-08-2023
Ciri produk Ciri produk Romania 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 01-08-2023
Risalah maklumat Risalah maklumat Slovak 31-08-2023
Ciri produk Ciri produk Slovak 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 01-08-2023
Risalah maklumat Risalah maklumat Slovenia 31-08-2023
Ciri produk Ciri produk Slovenia 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 01-08-2023
Risalah maklumat Risalah maklumat Finland 31-08-2023
Ciri produk Ciri produk Finland 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 01-08-2023
Risalah maklumat Risalah maklumat Sweden 31-08-2023
Ciri produk Ciri produk Sweden 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 01-08-2023
Risalah maklumat Risalah maklumat Norway 31-08-2023
Ciri produk Ciri produk Norway 31-08-2023
Risalah maklumat Risalah maklumat Iceland 31-08-2023
Ciri produk Ciri produk Iceland 31-08-2023
Risalah maklumat Risalah maklumat Croat 31-08-2023
Ciri produk Ciri produk Croat 31-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 01-08-2023

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen